Literature DB >> 33557065

Small Vessel Disease: Another Component of the Hypertrophic Cardiomyopathy Phenotype Not Necessarily Associated with Fibrosis.

Monica De Gaspari1, Cristina Basso1, Martina Perazzolo Marra1, Stefania Elia1, Maria Bueno Marinas1, Annalisa Angelini1, Gaetano Thiene1, Stefania Rizzo1.   

Abstract

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is characterized by myocardial disarray, small vessel disease (SVD), and fibrosis. The relationship between SVD and replacement-type fibrosis is still unclear.
METHODS: Histopathologic assessment of replacement-type fibrosis and SVD in HCM patients with either end-stage heart failure (HF) or sudden cardiac death (SCD). Chronic ischemic heart disease (IHD) patients served as controls.
RESULTS: Forty HCM hearts, 10 HF and 30 SCD, were studied. Replacement-type fibrosis was detected in all HF and in 57% of SCD cases. In SCD, replacement-type fibrosis was associated with older age, greater septal thickness, SVD prevalence, and score (all p < 0.05). Prevalence of SVD did not show significant differences among SCD, HF, and IHD (73%, 100% and 95%, respectively), while SVD score was higher in HF than IHD and SCD (2.4, 1.95, and 1.18, respectively) and in areas with replacement-type fibrosis vs. those without in HF (3.4 vs. 1.4) and SCD (1.4 vs. 0.8) (all p < 0.05).
CONCLUSIONS: SVD is a frequent feature in HCM independent of the clinical presentation. A higher SVD score is observed in HCM-HF and in areas with replacement-type fibrosis. Although SVD is part of the HCM phenotype, further remodeling of the microcirculation might occur secondarily to fibrosis.

Entities:  

Keywords:  hypertrophic cardiomyopathy; pathology; small vessel disease

Year:  2021        PMID: 33557065      PMCID: PMC7913811          DOI: 10.3390/jcm10040575

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  26 in total

Review 1.  Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations.

Authors:  Iacopo Olivotto; Giulia d'Amati; Cristina Basso; Albert Van Rossum; Monica Patten; Michele Emdin; Yigal Pinto; Benedetta Tomberli; Paolo G Camici; Michelle Michels
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

2.  Coronary microvascular dysfunction in hypertrophy and heart failure.

Authors:  Paolo G Camici; Carsten Tschöpe; Marcelo F Di Carli; Ornella Rimoldi; Sophie Van Linthout
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

3.  Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia.

Authors:  C Basso; G Thiene; D Corrado; G Buja; P Melacini; A Nava
Journal:  Hum Pathol       Date:  2000-08       Impact factor: 3.466

4.  Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease.

Authors:  A M Varnava; P M Elliott; S Sharma; W J McKenna; M J Davies
Journal:  Heart       Date:  2000-11       Impact factor: 5.994

5.  Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy.

Authors:  Paola Melacini; Cristina Basso; Annalisa Angelini; Chiara Calore; Fabiana Bobbo; Barbara Tokajuk; Nicoletta Bellini; Gessica Smaniotto; Mauro Zucchetto; Sabino Iliceto; Gaetano Thiene; Barry J Maron
Journal:  Eur Heart J       Date:  2010-05-31       Impact factor: 29.983

6.  Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death.

Authors:  Cristina Basso; Gaetano Thiene; Shannon Mackey-Bojack; Anna Chiara Frigo; Domenico Corrado; Barry J Maron
Journal:  Eur Heart J       Date:  2009-04-30       Impact factor: 29.983

7.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

Review 8.  Age-related changes in normal human hearts during the first 10 decades of life. Part II (Maturity): A quantitative anatomic study of 765 specimens from subjects 20 to 99 years old.

Authors:  D W Kitzman; D G Scholz; P T Hagen; D M Ilstrup; W D Edwards
Journal:  Mayo Clin Proc       Date:  1988-02       Impact factor: 7.616

9.  Morphometric investigation of human myocardium in arterial hypertension and valvular aortic stenosis.

Authors:  B Schwartzkopff; H Frenzel; J Dieckerhoff; P Betz; M Flasshove; H D Schulte; M Mundhenke; W Motz; B E Strauer
Journal:  Eur Heart J       Date:  1992-09       Impact factor: 29.983

10.  Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia.

Authors:  Deborah H Kwon; Nicholas G Smedira; E Rene Rodriguez; Carmela Tan; Randolph Setser; Maran Thamilarasan; Bruce W Lytle; Harry M Lever; Milind Y Desai
Journal:  J Am Coll Cardiol       Date:  2009-07-14       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.